ReviewCurrent gastroenterology reports2008
Diagnosis and management of cholangiocarcinoma.
Review in Current gastroenterology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.
- p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies.Digestive diseases and sciences · 2011Pooled it
- Recent Developments and Application of Mass Spectrometry Imaging in N-Glycosylation Studies: An Overview.Mass spectrometry (Tokyo, Japan) · 2024Review
- Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.Cancer research communications · 2023Article
- pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells.Materials (Basel, Switzerland) · 2022Article
- Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.Proteomics. Clinical applications · 2017Article
- Matrine induces RIP3-dependent necroptosis in cholangiocarcinoma cells.Cell death discovery · 2017Article
- Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells.OncoTargets and therapy · 2017Article
- Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells.International journal of nanomedicine · 2017Article
- Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.Oncotarget · 2016Article
- Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma.Drug design, development and therapy · 2015Article
- Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CC) is a rare yet frequently fatal tumor that causes significant morbidity and mortality due to late presentation. Radiology is the mainstay of CC diagnosis; however, advances in understanding the pathogenesis of CC, including the role of oncogenes, inflammation-mediated genomic instability, and interleukin-6/STAT-3 signaling pathways, may allow development of new diagnostic and prognostic markers and targets for CC therapy. Although surgical resection is the standard of care for resectable CC, liver transplantation has shown excellent results in selected patients. The use of chemotherapy and radiotherapy are currently limited by marginal response rates, toxicity, and biliary complications. Locally ablative therapies in the form of transcatheter arterial chemoembolization and radioembolization are under investigation. Molecular therapies (eg, epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor antagonists) and immunotherapy using diabodies are also under investigation for treatment of unresectable CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.